Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options. What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024. Why it Matters? These findings position...
about 1 month ago • 1 min read
Roche’s Itovebi Cuts Risk of Death by 33% in HER2-Positive Breast Cancer Context: HER2-positive breast cancer remains an aggressive subtype despite advances in targeted therapies. What's New? In updated data presented at ASCO, Roche’s anti-HER2 therapy Itovebi (trastuzumab duocarmazine) reduced the risk of death by 33% in pretreated HER2-positive breast cancer, significantly improving overall survival compared to standard therapies. Why it Matters? This reinforces Itovebi’s growing role in...
about 1 month ago • 1 min read
Genmab’s Endometrial Cancer Candidate Outperforms Expectations in Elahere-Competitive Space Context: The antibody-drug conjugate (ADC) market in gynecologic cancers is heating up, particularly following the success of ImmunoGen’s Elahere in ovarian cancer. What's New? Genmab and Seagen's ADC, currently in Phase 2, showed a 36% response rate in recurrent endometrial cancer, exceeding internal forecasts and prompting an accelerated push into Phase 3 development. Why it Matters? The results...
about 1 month ago • 1 min read
Merus Bispecific Shows “Unprecedented” Survival in Solid Tumors Context: Bispecific antibodies have shown early promise in hematologic cancers, but translating efficacy to solid tumors has remained a major hurdle. What's New? Merus reported that its HER3xCD3 bispecific zenocutuzumab (Zeno) achieved a median overall survival of 35.9 months in NRG1 fusion–positive tumors, a signal the company calls “unprecedented” for this molecular subtype. Shares jumped 35% on the news. Why it Matters? These...
about 1 month ago • 1 min read
FDA Approves First At-Home Cervical Cancer Screening Device Context: Cervical cancer screening remains underutilized, particularly among women facing barriers to in-person care. What's New? The FDA has approved the first self-collection device for HPV testing, allowing women to collect samples at home for laboratory-based cervical cancer screening. Why it Matters? This innovation may expand access to early detection, especially in underserved populations, and marks a pivotal shift in women’s...
about 1 month ago • 1 min read
Microsoft Unveils Agentic AI Platform for Personalized Cancer Care Context: AI in oncology has largely focused on diagnostics and documentation—but orchestration of real-time, personalized care remains a major frontier. What's New? Microsoft has launched an “agentic AI” orchestrator to assist oncologists with treatment decisions, patient navigation, and workflow optimization across cancer care. The technology integrates Copilot, Nuance, and Azure platforms with cancer center data streams. Why...
about 1 month ago • 1 min read
Repurposed Pinworm Drug Shows Activity in Merkel Cell Carcinoma Context: Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer with limited treatment options outside of immunotherapy. What's New? A new case series reports that pyrvinium pamoate, a decades-old anti-parasitic agent, led to tumor regression in patients with MCC. The drug is thought to act through mitochondrial inhibition and cancer metabolism pathways. Why it Matters? Repurposing well-characterized agents offers a...
about 1 month ago • 1 min read
Superior First-Line Prostate Cancer Treatment Underused Due to Low Awareness Context: Treatment intensification in metastatic hormone-sensitive prostate cancer has been shown to improve survival, yet implementation remains inconsistent. What's New? A recent study highlights that many patients are not receiving optimal first-line regimens such as novel hormonal therapies or chemotherapy, primarily due to lack of clinician awareness or familiarity with evolving guidelines. Why it Matters?...
about 2 months ago • 1 min read
Enliven Therapeutics Halts Phase 1 HER2 Solid Tumor Program Context: The pursuit of HER2-targeted therapies continues across solid tumors, but achieving a differentiated profile in a crowded space is increasingly difficult. What's New? Enliven Therapeutics announced it is discontinuing development of its HER2-targeted agent ELVN-002 after internal analyses suggested it would not be competitive with existing therapies in terms of safety, pharmacokinetics, and efficacy. Why it Matters? The...
about 2 months ago • 1 min read